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SUMMARY. In this work was evaluated the pharmacotherapeutic profile of HIV/AIDS bearers registered
in the Service of Specialized Attendance located in Campina Grande–PB, Brazil. The research was of the
type traverse, documental, descriptive and analytical and was realized in the period of August to October
2010. Were appraised the patient records of 188 people being 66 % males and 34% females. The most part
(36 %) just studied the education fundamental level and presented age group between 40-49 years old. An-
tiretrovirals more prescribed were nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside
reverse-transcriptase inhibitors (NNRTIs). Schemes no recommended by the Ministry of Health also were
evidenced. The Negative Results associated to the use of medicine was registered in the three supra-cate-
gories. It is necessary a larger integration of the multidisciplinary team of prescribers (physicians and den-
tists) and pharmacists in the evaluation of the pharmacotherapy to guarantee the reduction of the morbid-
ity and the presence of opportunists infections, guaranteeing so a better surviving for the seropositive pa-
tients.
